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Rationale: Formoterol is approved as asthma rescue medication in many countries. The
exact duration of the airway vs. systemic effects of formoterol compared with another
rescue medication, salbutamol, has not been evaluated.
Objective: To assess the duration of airway bronchodilatory effects vs. systemic effects of
inhaled formoterol and salbutamol in asthmatic patients.
Methods: Twenty-six patients with stable and reversible asthma were given single doses of
formoterol dry-powder inhaler (OxissTurbuhalers) 2 9mg (lower dose; LD) and 6 9 mg
(higher dose; HD), salbutamol (VentolinsDiskhalers) 3 400 mg (LD) and 9 400 mg (HD),
and placebo in a randomized, double-blind, crossover trial. Airway and systemic effects
were assessed by forced expiratory volume in 1 s (FEV1), serum potassium, blood pressure,
corrected QT-interval (QTc), and palpitation and tremor scores. Time with clinically
relevant bronchodilation (FEV1 increase X12%) without clinically relevant markers of
systemic effects (serum potassium suppression X0.2mmol/L, QTc-prolongation X20ms,
or heart rate increase X8 beats per minute) was evaluated.
Results: Bronchodilation was maintained for 24 h with both formoterol doses and for
7–11 h with salbutamol. Maximum bronchodilation and systemic effects were similar after
formoterol and salbutamol, except for statistically significantly larger maximum heart rate
and palpitation and tremor scores after salbutamol. Systemic responses were similarly
brief for formoterol and salbutamol (p7 h).
Conclusions: The airway effects of inhaled formoterol are of long duration, whereas the
systemic effects are of a similarly short duration as salbutamol. Thus, the time with
clinically relevant bronchodilation without systemic effects is substantially longer after
formoterol than after salbutamol.
& 2007 Published by Elsevier Ltd.Published by Elsevier Ltd.
Zeneca.
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J. Lo¨tvall, J. Ankerst450Introduction forced expiratory volume in 1 s (FEV1), serum potassium,The introduction of the inhaled long-acting b2-agonists
formoterol and salmeterol over a decade ago has proven
to be a great advancement in the management of asthma,
providing effective bronchodilation and long-term improve-
ment in lung function, as well as a reduction in the
frequency of asthma exacerbations when given in addition
to inhaled glucocorticoids.1,2 These two long-acting b2-
agonists, however, have different pharmacologic profiles
enabling different clinical uses. Formoterol has a rapid onset
of action, which is similar to that of salbutamol and clearly
more rapid than that of salmeterol.3,4 Of perhaps greater
importance is the fact that formoterol is a full b2-receptor
agonist whereas salmeterol is a partial agonist, as evident
from formoterol’s greater maximal bronchoprotective effect
compared with salmeterol.5,6 In severely bronchocon-
stricted airways, a greater degree of b2-receptor activation
is required to induce relaxation of the bronchial smooth
muscle, which would suggest that formoterol could be used
in acute severe asthma, but not salmeterol. In fact,
formoterol has proven to be as effective as salbutamol in
the treatment of patients with acute asthma in an
emergency room setting.7 Furthermore, the very large
‘‘real-life’’ RELIEF study, comparing formoterol and salbu-
tamol for every-day rescue medication, showed improved
asthma control in patients using formoterol.8
Concerns have been expressed that the systemic effects
of formoterol could be of long duration, especially when
high doses are used for rescue medication or in the
treatment of acute asthma. However, some previous studies
suggest that the systemic effects of formoterol remain
short, whereas the airway effects are of long duration.9,10
This double-blind crossover study was performed to assess
the duration and magnitude of bronchodilation in relation to
systemic side effects of salbutamol 1200 and 3600 mg and
formoterol 18 and 54 mg. To evaluate any differences in
duration of both airway and systemic effects, we monitored
patients for 24 h after inhalation of the two b2-agonists. The
objective of this study was therefore to estimate the
duration of the beneficial pulmonary effects provided by
the drugs without the occurrence of systemic side effects.
Methods
Overall study design
A total of 26 patients with stable asthma were included in
the study (study code SD-037-0744), which was a double-
blind, double-dummy, placebo-controlled, single-dose study
with a five-way, randomized crossover design performed in
two centers (Go¨teborg University and Lund University
Hospital, Sweden). The study was approved by the local
ethics committees, as well as by the Swedish Medical
Product Agency (Uppsala, Sweden). The study was mon-
itored according to the principles of Good Clinical Trial
Practice (GCTP).
Informed consent, laboratory screening, and patient
eligibility were acquired/assessed over two initial visits.
The experimental visits (Visits 3–7) constituted the cross-
over part of the study, with repeated measurements ofblood pressure, electrocardiogram (ECG), and tremor and
palpitations up to 14 h after drug administration. Patients
were then allowed to leave the clinic but returned the
following morning for further assessments of FEV1 and serum
potassium 24 h after drug administration. At least 72 h but
not more than 14 days elapsed between visits.
Nonsmoking patients with stable asthma for at least 6
months, as defined according to the ATS definition,11 aged
X18 years were eligible to participate in the study. Baseline
FEV1 was required to be X60% of predicted normal and
X1.5 L. At inclusion, patients had to demonstrate a
reversibility of X15% of the basal FEV1 value 20–30min
after inhalation of 2 0.5mg terbutaline sulfate via
Turbuhaler. Patients were excluded if they had experienced
a lower respiratory tract infection within 30 days prior to
Visit 1 or had any other significant disease or disorder.
Patients were also excluded if they had a smoking history of
more than 15 pack-years or if they had a clinical history of
relevant arrhythmias or other heart disease.
For all randomized patients, mean baseline FEV1 at each
study visit was required to be within 712% of baseline FEV1
measured at the enrollment visit.
Single doses of formoterol (Oxiss) Turbuhalers 2 9 mg
(lower dose, LD) and 6 9 mg, (higher dose, HD), salbutamol
(Ventolins) Diskhalers 3 400 mg lower dose and 9 400 mg,
higher dose and placebo were given at Visits 3–7. All 15
doses were to be inhaled consecutively according to the
manufacturer’s instruction over a 5-min period (maximum)
and within 20min of the first baseline measurements. Zero
time (reference time) was set as the time of the first
inhalation. The order of administration of the active
medications was randomized between patients in order to
avoid interference between the timing of the dose and the
results (odd numbers started inhaling from Turbuhaler, even
numbers started inhaling from Diskhaler). The doses given
were matched to a dose-range expected to be used in acute
situations, up to the maximum daily dose approved for
clinical use.Assessments
Postdose spirometry tests during experimental days were
performed at 10, 15, 30, 60min, and every hour thereafter
until 14 h after the first inhalation of study drug, and in
addition in the morning 24 h after dosing. Serum potassium,
blood pressure, and ECG (corrected QT-interval (QTc) and
heart rate) were monitored approximately 10min before
inhalation of study drug, at 30 and 60min after the first
inhalation of study drug, and every hour thereafter until 14 h
(and for serum potassium only, in the morning 24 h after
dosing). Tremor and palpitations were scored 10min before
inhalation of study drug, at 10, 15, 30, and 60min after the
first inhalation of study drug, and thereafter every hour until
14 h post-inhalation. Patients were to stay indoors at the
clinic until the 14-h postdosing assessments had been
completed, but they returned to the clinic the next morning
to complete the 24-h postdosing measurements. Patients
were asked to avoid alcoholic and/or caffeinated beverages
and physical exercise for 12 h prior to and during the
treatment visits, and were asked to arrive at the clinic
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Duration of airway and systemic effects of formoterol 451fasting. Lunch and dinner were served at 4 and 8 h
postdosing and a snack was served at 12 h during the
treatment days. The menus were potassium-reduced in
order to avoid excessive changes in potassium as a result of
food intake.
Serum was prepared from blood sampled without stasis in
a 3mL tube with anticoagulant. The collected blood was to
be gently tilted up and down 7–10 times, placed in an
upright position for about 30min, and then centrifuged at
1400g for 10min. The supernatant serum was collected and
frozen at 20 1C. A 12-lead ECG was recorded in order to
define heart rate and QTc. The systolic and diastolic blood
pressure were measured using the cuff method appropriate
for arm circumference. Tremor and palpitations were scored
using a four-point scale: none, mild, moderate, or severe.Table 1 Demography and baseline characteristics.
Variable Patients (n ¼ 26)
Male, n (%) 18 (69)
Age (year) 39.3 (21–66)
Body mass index (kg/m2) 26.1 (19–38)
FEV1 (L) 3.12 (1.70–4.46)
FEV1 (% predicted normal) 81.4 (60.9–102.7)
Reversibility (%) 20.6 (15.1–36.6)
Heart rate (beats per minute) 63 (48–76)
Systolic blood pressure (mmHg) 119 (96–140)
Diastolic blood pressure (mmHg) 73 (56–90)
Serum potassium (mmol/L) 4.0 (3.3–4.6)
Treatment at entry
Long-acting b2-agonists, n (%) 7 (27)
Inhaled glucocorticosteroids, n (%) 23 (88)
Dose (mg/day) 529 (200–800)
All values presented as mean (range) unless specified. FEV1,
forced expiratory volume in 1 s.Sample size determination and data analysis
Twenty-four evaluable patients were considered sufficient
to assess the primary objective of a difference between
formoterol and salbutamol, and to detect any relevant dose-
dependent differences. Assuming a within-patient coeffi-
cient of variation of 6%, this sample size would allow
detection of a pairwise difference in FEV1 between two
treatments of 5% with 80% probability, using a two-sided
alternative at a 5% significance level. Similarly for serum
potassium, assuming a residual standard deviation of
0.25mmol/L, a pairwise difference of 0.21mmol/L could
be detected.
To perform statistics on relevant changes in lung function
and systemic parameters, we needed to predetermine which
changes could be viewed as ‘‘clinically relevant’’. For this
estimation, we aimed to be conservative, requiring rela-
tively high changes in lung function, but allowing any
systemic effects to be numerically relatively small. Thus, we
determined that any ‘‘relevant’’ change in FEV1 needed to
be at least 12% greater than the predose baseline. What we
have labeled as ‘‘clinically relevant’’ changes in systemic
parameters were set at relatively low specified levels—
rationally balanced between changes measurable with the
methodology used and what can be deemed to cause
symptoms in most patients. These levels were set as a
decrease in serum potassium of X0.2mmol/L, a QTc
increase X20ms, and an increase in heart rate X8 beats
per minute (bpm) (all relative to baseline). Any change in
tremor score was judged to be clinically relevant.
The primary endpoint was duration of bronchodilation
without systemic effects, assessed as the time with FEV1
response (increase X12% relative to baseline) minus the
time with a response in serum potassium (decrease
X0.2mmol/L relative to baseline). For analysis, the
response times for FEV1 and serum potassium were
determined for each patient and treatment, and compared
as dependent variables in an additive multivariate analysis
of variance model with patient, period, and treatment as
fixed factors. The response times for FEV1 were similarly
related to the response times for QTc (increase X20ms
relative to baseline) and heart rate (increase X8 bpm
relative to baseline).
Analysis of variance models (with patient, period, and
treatment as fixed factors) were used to evaluate peaktreatment effects, and effects at specific timepoints for
FEV1, serum potassium, heart rate, QTc, blood pressure,
tremor, and palpitation. The baseline (predrug administra-
tion) measurement was used as a covariate. Multiplicative
models were used to evaluate the effect on FEV1.
4,12 All
tests were two sided at a 5% significance level, and required
at least two study visits to have been performed.
Results
A total of 36 patients were enrolled at the two centers, of
whom 26 patients were allocated to receive study drug
treatment. Patient characteristics are summarized in Table
1. The median time since diagnosis of asthma was 22 years
(range: 5–53 years). In total, three randomized patients
discontinued the study. One female patient discontinued the
study due to ST-segment depression after the highest dose of
salbutamol (3600 mg); however, there was no sign of
myocardial enzyme changes following biochemistry testing,
and ECG changes disappeared spontaneously. A second
patient was excluded due to gastrointestinal infection, and
a third patient was excluded due to technical problems with
blood sampling.
The analysis set consisted of all randomized and treated
patients with data collected from at least two study visits.
For the primary efficacy variables, 25 of the 26 randomized
patients had data that could be used for the statistical
analysis. One subject only participated in one study day and
was therefore not included in the full analysis. The patient
flow is summarized in Figure 1.
Both salbutamol and formoterol improved FEV1 at 10min
(Figure 1A). The bronchodilatory effect of salbutamol
started to decline after 4 h but was still statistically
significantly higher than placebo at 7 h after dosing (relative
difference 3%) and 11 h (6%), for low- and high-dose
salbutamol, respectively. By contrast, the effect of for-
moterol was maintained and remained statistically signifi-
cantly higher than placebo at 24 h (relative difference: low
dose 10%, high dose 12%).
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J. Lo¨tvall, J. Ankerst452Both doses of salbutamol and the higher dose of
formoterol caused a statistically significant reduction in
serum potassium at 30min, but the effects on potassium
declined rapidly for both b2-agonists (Figure 1B). From 5h
onwards, i.e. after first food intake, effects on serum
potassium were small compared with placebo and similar for
the two drugs.
Figure 3 shows the time with a clinically relevant
improvement in FEV1 without relevant effects on serum
potassium over the 24 h postdosing, and the details of the
results are summarized in Table 2. There was a statistically
significantly longer gain in airway effects vs. systemic
effects with formoterol compared with salbutamol for both
the higher (6.3 h) and lower (11.0 h) dose levels (Table 2).
After receiving placebo, few patients reached the response
level in FEV1 but 12 patients did so for the serum potassium
response, probably because of a temporary effect on
gastrointestinal blood flow due to food intake.13,14
The mean time profiles of QTc and heart rate are shown in
Figure 2A and B. Maximum treatment effects and inter-
treatment differences are summarized in Table 3. Effects on
QTc declined rapidly for both drugs and were no longer10
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Figure 1 Change in FEV1(L) and S-potassium (mmol) over 24 h
after single doses of inhaled formoterol (18 and 54 mg) and
inhaled salbutmaol (1200 and 3600 mg).statistically significant vs. placebo at 2 h. Dose-dependent
effects were observed for heart rate, which for the higher
doses of both formoterol and salbutamol remained statisti-
cally significant vs. placebo during the 14-h assessment
period. During the first 4 h, the effects of salbutamol on
heart rate were more marked than the effects observed
after formoterol (Figure 2B). The time profiles for effects
of the different treatments on tremor are illustrated in
Figure 2C.
The time with improvement in FEV1 without undesired
effects on QTc and heart rate during the first 14 h postdosing
is summarized in Table 2. There was a statistically
significantly longer net gain of bronchodilation with for-
moterol compared with salbutamol with respect to QTc (5 h
at the lower dose level) and heart rate (4–5 h at both dose
levels). About half the number of patients ‘‘responded’’ to
placebo for the heart rate parameter after 4 h (increases
X8 bpm), probably because of a temporary effect on
gastrointestinal blood flow due to food intake.8
Maximum treatment effects and intertreatment differ-
ences are summarized in Table 3. All effects were
statistically significant compared with placebo, except for
QTc and heart rate increases following the low dose of
formoterol, and palpitation score following the low doses of
both formoterol and salbutamol. Maximum bronchodilation
after formoterol and salbutamol was similar at both dose
levels. A small but statistically significant potential for
improvement in FEV1 from the lower to the higher dose level
was seen with both drugs. Maximum systemic effects were
similar at the two dose levels, except for statistically
significantly larger effects observed with salbutamol for
maximum heart rate and palpitation score at the higher
dose level and for maximum tremor score, both at the
higher and lower dose levels, compared with the corre-
sponding formoterol doses (Table 3). The time in response in
FEV1 and serum potassium are illustrated in Figure 3A and B,
and the difference between these parameters are shown in
Figure 3C.
Adverse events were reported in 11 and 10 patients
receiving low- and high-dose formoterol, respectively. The
number of patients with adverse events with low- and high-
dose salbutamol was 5 and 13, respectively, with 8 patients
reporting adverse events with placebo. The most commonly
reported adverse event was headache. No serious adverse
events were reported.Discussion
This single-dose, double-blind, crossover study in patients
with asthma demonstrates that the airway bronchodilatory
effect of inhaled formoterol is sustained over 24 h, but that
the systemic effects have a substantially shorter duration,
as evaluated by serum potassium, QTc, and tremor and
palpitation scores. In fact, the systemic effects of formoter-
ol have a similar time course as those induced by
salbutamol. This means that increased doses of formoterol
have an extended therapeutic benefit over time, providing
long-lasting airway effects without any prolonged systemic
side effects.
Importantly, the sustained bronchodilation seen over 24 h
with inhaled formoterol was similar at the two dose levels
ARTICLE IN PRESS
Table 2 Duration of clinically relevant effects relative to baseline for lung function (FEV1), serum potassium, QTc and heart
rate after single doses of formoterol or salbutamol.
Time (min) with response Estimated treatment difference
(95% confidence limits)
Formoterol Salbutamol Formoterol (LD) vs.
salbutamol (LD)
Formoterol (HD) vs.
salbutamol (HD)
LD HD LD HD
24-h assessmentsy
FEV1 907 984 408 553
S-K+ 297 469 455 415
Time with FEV1 and
without S-K+ response
610 516 47 138 658 [6.3 h] (337, 978)
po0.001
378 [11.0 h] (58, 697)
p ¼ 0.02
14-h assessmentsz
FEV1 626 636 396 470
QTc 64 182 127 152
HR 113 400 174 512
Time with FEV1 and
without QTc response
562 453 269 318 293 [5.0 h] (141, 445)
po0.001
135 [2.3 h] (19, 290)
p ¼ 0.08
Time with FEV1 and
without HR response
513 236 222 42 292 [4.9 h] (131, 453)
po0.001
278 [4.6 h] (114, 441)
po0.001
FEV1, forced expiratory volume in 1 s. LD, lower doses (formoterol 18mg or salbutamol 1200 mg). HD, higher doses (formoterol 54mg or
salbutamol 3600mg).
Clinically relevant effects vs. baseline: FEV1: increase X12%; S-K
+: decrease X0.2mmol/L; QTc: increaseX20ms; HR: increase 8
beats per minute.
y24-h joint monitoring of FEV1 and S-K
+.
z14-h joint monitoring of FEV1, QTc, and HR.
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Figure 2 Mean change in (A) QTc interval, (B) heart rate and (C) Tremor score over a 14-h period after single doses of formoterol (18
or 54mg) and salbutamol (1200 and 3600 mg).
Duration of airway and systemic effects of formoterol 453(18 and 54 mg). Thus, both doses of formoterol showed a
similar elimination rate for FEV1, arguing that formoterol’s
duration of airway effect in relation to the observed
maximal effect is independent of the dose given.3,4
The primary aim of this study, however, was to compare
the duration of systemic effects with high doses of
formoterol with those observed with high doses of thealternative rescue b2-agonist, salbutamol. A previous study
of repeated dosing with formoterol suggested that the
duration of systemic effects was surprisingly short.9,10,15 The
current study—directly comparing the systemic effects of
two carefully chosen doses of salbutamol and formoterol—
clearly shows that the systemic effects of these two drugs
are of similar duration. Furthermore, the comparable
ARTICLE IN PRESS
Table 3 Maximum treatment effects after single doses of formoterol, salbutamol, and placebo given as adjusted mean
change from baseline.
Parameter Maximum change vs. baseline Treatment difference
formoterol–salbutamol
(95% confidence limits)
p-Value
Placebo
mean
Dose levels Formoterol
mean
Salbutamol
mean
FEV1 (%) 111 LD 124
 122 1.9 (0.2, 4.0) 0.08
HD 127 126 0.3 (1.8, 2.4) 0.77
S-K+ (mmol/L) 0.40 LD 0.48 0.48 0.0 (0.17, 0.16) 0.96
HD 0.63 0.72 0.09 (0.08, 0.26) 0.30
QTc (ms) 23.5 LD 26.2 31.6 5.5 (12.0, 1.1) 0.10
HD 32.4 30.7 1.7 (4.9, 8.3) 0.61
HR (beats per
minute)
10.2 LD 12.2 13.4 1.2 (4.2, 1.8) 0.44
HD 17.4 25.6 8.2 (11.2, –5.1) o0.001
Tremor score (four-
point scale)
0.1 LD 0.4 0.7 0.3 (0.5, –0.0) 0.02
HD 0.9 1.4 0.5 (0.8, –0.3) o0.001
Palpitation score
(four-point scale)
0.0 LD 0.1 0.2 0.1 (0.4, 0.2) 0.68
HD 0.5 1.3 0.8 (1.1, –0.5) o0.001
FEV1, forced expiratory volume in 1 s. S-K+, serum potassium. Q-Tc, corrected Q-T interval. HR, heart rate. LD, lower doses (formoterol
18mg or salbutamol 1200 mg). HD, higher doses (formoterol 54mg or salbutamol 3600 mg).
Statistically significant vs. placebo.
J. Lo¨tvall, J. Ankerst454duration of systemic effects of formoterol and salbutamol
was evident regardless of whether the indicative measure-
ment was for serum potassium, QTc interval, heart rate,
blood pressure, or tremor score (Figure 2B). From our
findings, it can be concluded that there is no disadvantage of
using formoterol rather than salbutamol for rescue medica-
tion with respect to the systemic safety profile.
The mechanisms that explain the different duration of
airway and systemic effects of formoterol cannot be related
to the properties of the b2-receptor, as these are structu-
rally similar regardless of the tissue in which the receptors
are expressed.16 In contrast, it seems that the much lower
concentrations of formoterol obtained in extrapulmonary
tissues following inhalation are clearly insufficient to
provide a long duration of systemic effect. In fact, it
has been suggested previously that formoterol’s long
duration of effect is due to its moderately lipophilic nature,
which is resulting in a depot effect of the drug in airway
lipid tissue, possibly including the cell membranes.17 This
conclusion is supported by an earlier study showing that
inhaled but not oral formoterol causes long-lasting improve-
ment in lung function.18 The long duration of locally
mediated effects of inhaled formoterol could therefore be
explained by sustained concentrations of formoterol in the
airway wall close to the smooth muscle, but not in
peripheral tissue. In contrast, the short duration of systemic
and airway effects of oral formoterol could only be
explained by a sufficiently large transient concentration of
formoterol inside as well as outside the airways. Therefore,
the short duration of effect in the airways of oral
formoterol, as well as the short duration of systemic effects
of both oral and inhaled formoterol, may be primarily driven
by the pharmacokinetics of formoterol, with a half-lifeapproximately corresponding to the duration of systemic
side effects.19,20
Formoterol has been approved for use as a rescue b2-
agonist in the treatment of asthma in Europe. The
characteristics that enabled formoterol to be approved for
rescue medication use include its rapid onset of action and
high pharmacologic efficacy.4–6 Evidence from larger clinical
studies supporting the use of formoterol as rescue medica-
tion came initially from a double-blind study by Tattersfield
et al.21 In this study, adult patients with moderate asthma
were given formoterol 4.5 mg or terbutaline 0.5mg for
rescue medication, and the findings demonstrated that
patients using rescue formoterol had better asthma control
and fewer severe exacerbations compared with the group
taking terbutaline for rescue medication.21 The effective-
ness of formoterol as reliever medication was later
confirmed by the large RELIEF study.8 A total of 18,124
asthma patients were given either formoterol or salbutamol
for reliever medication over a 6-month period. Patients
receiving formoterol had better overall asthma control, as
determined by exacerbation frequency, compared with
patients receiving salbutamol.8 Furthermore, formoterol
for reliever therapy has been found to be as safe and
effective as terbutaline in patients with mild persistent or
intermittent asthma.22 The current study was specifically
designed to compare the duration of systemic effects with
the duration of airway effects of inhaled formoterol vs.
salbutamol, and our findings have subsequently confirmed
the safety of high doses of formoterol.
In summary, the current study shows that despite its
longer bronchodilatory effect, formoterol has systemic side
effects of a similarly short duration as the short-acting
b2-agonist salbutamol. There should, therefore, be no
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Figure 3 Time with clinically relevant bronchodilation (forced
expiratory volume in 1 s [FEV1] increase X12% in relation to
baseline [white bars]) and time with clinically relevant effect
on serum potassium (S-K+ decrease X0.2mmol/L in relation to
baseline [shaded bars]) over a 24-h period after single doses of
formoterol (18 or 54 mg) and salbutamol (1200 and 3600 mg). The
difference in height between the two bars illustrates a situation
where the duration of bronchodilation is longer for formoterol
(18 or 54mg) and potentially shorter with salbutamol (1200 mg)
than the corresponding systemic effect on serum potassium.
Duration of airway and systemic effects of formoterol 455therapeutic disadvantage in using formoterol in doses up to
54 mg compared with using salbutamol in doses up to 3600 mg
for rescue treatment during episodes of airflow obstruction.Conflict of interest
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